Evidence map›Paper›PMID 28115246›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2017

Imaging the delivery of drug-loaded, iron-stabilized micelles.

Suzanne J Bakewell, Adam Carie, Tara L Costich, Jyothi Sethuraman, J Edward Semple, Bradford Sullivan, Gary V Martinez, William Dominguez-Viqueira, Kevin N Sill

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03096340 (A Phase 1 With Expansion Cohort, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenously Infused IT-141 in Subjects With Recurrent or Refractory Solid Tumors), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03096340 phase1terminatednot on this map

A Phase 1 With Expansion Cohort, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenously Infused IT-141 in Subjects With Recurrent or Refractory Solid Tumors

TypeinterventionalSponsorIntezyne Technologies, Inc.Ran2017 to 2019Enrolled10ConditionsCancer, Neoplasms, Tumors, Refractory Solid TumorsArmsIT-141
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. FeInternational journal of nanomedicine · 2023
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Suzanne J BakewellIntezyne Technologies, Tampa, FL, USA. Electronic address: suzanne.bakewell@intezyne.com.
Adam CarieIntezyne Technologies, Tampa, FL, USA.
Tara L CostichIntezyne Technologies, Tampa, FL, USA.
Jyothi SethuramanIntezyne Technologies, Tampa, FL, USA.
J Edward SempleIntezyne Technologies, Tampa, FL, USA.
Bradford SullivanIntezyne Technologies, Tampa, FL, USA.
Gary V MartinezDepartment of Cancer Imaging and Metabolism, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
William Dominguez-ViqueiraDepartment of Cancer Imaging and Metabolism, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Kevin N SillIntezyne Technologies, Tampa, FL, USA.
Intezyne (United States) · USMoffitt Cancer Center · USTeledyne Technologies (United States) · US

Funding

Micellar Daunorubicin for the Treatment of Bone CancerU43CA179468 · NCI · INTEZYNE TECHNOLOGIES, LLC · PI SILL, KEVIN N · 2014 to 2014
$157k
NCI NIH HHS HHSN261201400018CNCI NIH HHS U43 CA179468
6 · The paper itself

Abstract

Nanoparticle drug carriers hold potential to improve current cancer therapy by delivering payload to the tumor environment and decreasing toxic side effects. Challenges in nanotechnology drug delivery include plasma instability, site-specific delivery, and relevant biomarkers. We have developed a triblock polymer comprising a hydroxamic acid functionalized center block that chelates iron to form a stabilized micelle that physically entraps chemotherapeutic drugs in the hydrophobic core. The iron-imparted stability significantly improves the integrity of the micelle and extends circulation pharmacokinetics in plasma over that of free drug. Furthermore, the paramagnetic properties of the iron-crosslinking exhibits contrast in the tumors for imaging by magnetic resonance. Three separate nanoparticle formulations demonstrate improved anti-tumor efficacy in xenograft models and decreased toxicity. We report a stabilized polymer micelle that improves the tolerability and efficacy of chemotherapeutic drugs, and holds potential for non-invasive MRI to image drug delivery and deposition in the tumor.

Indexed as

MicellesAnimalsAntineoplastic AgentsBreast NeoplasmsCell Line, TumorColorectal NeoplasmsDrug CarriersFemaleHumansIronMagnetic Resonance ImagingMice, NudePolymersRats, Sprague-DawleyXenograft Model Antitumor AssaysAntineoplastic AgentsDrug CarriersIronMicellesPolymersChemotherapeuticsIron-stabilizationMRI agentPolymer micelleTargeted delivery

Identifiers

PMID28115246
PMCPMC5451294
OpenAlexW2573119684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.